Loghavi Sanam, Khoury Joseph D
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 0072, Houston, TX, 77030, USA.
Curr Hematol Malig Rep. 2018 Dec;13(6):446-454. doi: 10.1007/s11899-018-0475-5.
The goal of this review is to provide a practical and comprehensive update on changes in the classification of chronic myelomonocytic leukemia (CMML) and a summary of the most recent developments in our understanding of its genomic landscape, prognostic models, and therapeutic approaches.
The 2017 revision of the World Health Organization (WHO) classification includes substantial changes to the subclassification CMML. The clinical utility of the newly revised subclassification scheme is discussed. In addition, we provide an overview of the genetic changes involved in the pathogenesis of CMML and discuss the clinical utility of the more recently developed molecularly integrated prognostic models and their management and therapeutic implications. Finally, we provide an overview of the currently available treatment options for patients with CMML. The classification of CMML as well as our understanding of its genomic landscape and optimal treatment approaches has advanced significantly over the past decade but remains in flux.
本综述旨在对慢性粒单核细胞白血病（CMML）分类的变化进行实用且全面的更新，并总结我们对其基因组格局、预后模型和治疗方法理解的最新进展。
世界卫生组织（WHO）2017年修订的分类对CMML的亚分类有重大改变。讨论了新修订的亚分类方案的临床实用性。此外，我们概述了CMML发病机制中涉及的基因变化，并讨论了最近开发的分子综合预后模型的临床实用性及其管理和治疗意义。最后，我们概述了CMML患者目前可用的治疗选择。在过去十年中，CMML的分类以及我们对其基因组格局和最佳治疗方法的理解有了显著进展，但仍在不断变化。
